| Mar'20 | Dec'19 | Sep'19 | Jun'19 | Mar'19 | Dec'18 | Sep'18 | Jun'18 | Mar'18 |
|---|---|---|---|---|---|---|---|---|
Revenue: | ||||||||
Total revenue | ||||||||
22,785 | 21,219 | 24,363 | 28,170 | 28,362 | 27,508 | 0 | 0 | 0 |
Grant revenue | ||||||||
- | - | - | - | - | 169 | 0 | 0 | 0 |
Total revenue | ||||||||
- | - | 24,363 | 28,170 | - | 27,677 | 0 | 0 | 0 |
Operating expenses: | ||||||||
Research and development | ||||||||
114,526 | 100,528 | 98,863 | 90,736 | 81,914 | 73,031 | 0 | 0 | 0 |
General and administrative | ||||||||
43,980 | 35,095 | 26,579 | 21,179 | 15,272 | 11,934 | 0 | 0 | 0 |
Total operating expenses | ||||||||
158,506 | 135,623 | 125,442 | 111,915 | 97,186 | 84,965 | 0 | 0 | 0 |
Loss from operations | ||||||||
-135,721 | -114,404 | -101,079 | -83,745 | -68,824 | -57,288 | 0 | 0 | 0 |
Other income, net | ||||||||
8,877 | 9,019 | 8,848 | 7,935 | 6,453 | 5,040 | 0 | 0 | 0 |
Net loss | ||||||||
-126,844 | -105,385 | -92,231 | -75,810 | -62,371 | -52,248 | 0 | 0 | 0 |
Unrealized gain on marketable securities | ||||||||
2,674 | 184 | 366 | 533 | 262 | -42 | 0 | 0 | 0 |
Comprehensive loss | ||||||||
-124,170 | -105,201 | -91,865 | -75,277 | -62,109 | -52,290 | 0 | 0 | 0 |
Net loss per share, basic and diluted | ||||||||
-0.53 | -0.46 | -0.47 | -0.36 | -0.42 | -1.50 | -1.34 | -1.00 | -0.78 |
Shares used in computing net loss per share, basic and diluted | ||||||||
74,820 | 68,209 | 67,572 | 67,327 | 43,828 | 11,754 | 11,441 | 11,157 | 10,858 |